Zhang Chenxiong, Tan Hao, Xu Han, Ding Jiaming, Chen Huijuan, Liu Xiaohong, Sun Feng
Department of Proctology, Yubei Hospital of Traditional Chinese Medicine, Chongqing Yubei District, Chongqing, 401120, China.
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, 510403, China.
Heliyon. 2024 Mar 16;10(7):e28005. doi: 10.1016/j.heliyon.2024.e28005. eCollection 2024 Apr 15.
ARPC1B encodes the protein known as actin-related protein 2/3 complex subunit 1 B (ARPC1B), which controls actin polymerization in the human body. Although ARPC1B has been linked to several human malignancies, its function in these cancers remains unclear. TCGA, GTEx, CCLE, Xena, CellMiner, TISIDB, and molecular signature databases were used to analyze ARPC1B expression in cancers. Visualization of data was primarily achieved using R language, version 4.0. Nineteen tumors exhibited high levels of ARPC1B expression, which were associated with different tumor stages and significantly affected the prognosis of various cancers. The level of ARPC1B expression substantially connected the narrative of ARPC1B expression with several TMB cancers and showed significant changes in MSI. Additionally, tolerance to numerous anticancer medications has been linked to high ARPC1B gene expression. Using Gene Set Variation Analysis/Gene Set Enrichment Analysisanalysis and concentrating on Rectum adenocarcinoma (READ), we thoroughly examined the molecular processes of the ARPC1B gene in pan-cancer. Using WGCNA, we examined the co-expression network of READ and ARPC1B. Meanwhile, ten specimens were selected for immunohistochemical examination, which showed high expression of ARPC1B in READ. Human pan-cancer samples show higher ARPC1B expression than healthy tissues. In many malignancies, particularly READ, ARPC1B overexpression is associated with immune cell infiltration and a poor prognosis. These results imply that the molecular biomarker ARPC1B may be used to assess the prognosis and immune infiltration of patients with READ.
ARPC1B编码一种名为肌动蛋白相关蛋白2/3复合物亚基1B（ARPC1B）的蛋白质，该蛋白质控制人体中的肌动蛋白聚合。尽管ARPC1B与多种人类恶性肿瘤有关，但其在这些癌症中的功能仍不清楚。使用TCGA、GTEx、CCLE、Xena、CellMiner、TISIDB和分子特征数据库来分析ARPC1B在癌症中的表达。数据可视化主要使用R语言4.0版本实现。19种肿瘤表现出高水平的ARPC1B表达，这与不同的肿瘤分期相关，并显著影响各种癌症的预后。ARPC1B的表达水平将ARPC1B表达的叙述与几种肿瘤突变负荷（TMB）癌症紧密联系起来，并在微卫星不稳定性（MSI）方面显示出显著变化。此外，对多种抗癌药物的耐受性与ARPC1B基因的高表达有关。通过基因集变异分析/基因集富集分析，并聚焦于直肠腺癌（READ），我们全面研究了ARPC1B基因在泛癌中的分子过程。使用加权基因共表达网络分析（WGCNA），我们研究了READ和ARPC1B的共表达网络。同时，选择了10个样本进行免疫组织化学检查，结果显示READ中ARPC1B高表达。人类泛癌样本显示出比健康组织更高的ARPC1B表达。在许多恶性肿瘤中，尤其是READ，ARPC1B的过表达与免疫细胞浸润和不良预后相关。这些结果表明，分子生物标志物ARPC1B可用于评估READ患者的预后和免疫浸润情况。
